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Stage 4s neuroblastoma (NB) is usually associated with a favourable outcome, despite a large tumour burden, as spontaneous
regression frequently occurs. However, in some infants rapid disease progression can be observed with severe functional impairment.
Thus, for all patients the potential risks of cytotoxic therapy must be weighed against the benefits of early medical intervention. We
have retrospectively reviewed the charts of 94 infants treated for stage 4s NB in centres of the French Society of Paediatric Oncology
between 1990 and 2000, and describe the different first-line treatment approaches that were, successively, liver irradiation,
chemotherapy using a cyclophosphamide–vincristine regimen, and chemotherapy using a carboplatin–etoposide regimen. The
overall survival was 88% (77.6%), with a mean follow-up of 64 months. Elevated serum neuron-specific enolase (4100nmolml
 1),
ferritin (4280ngml
 1) and urinary dopamine levels (42500nmolmmol
 1 creatinine) were associated with a poor outcome, as
were the genetic markers N-myc amplification and chromosome 1p deletion (Po0.0005 and P¼0.0016, respectively). Patients who
required medical intervention at diagnosis fared worse than those who received supportive treatment only (Po0.005). The clinical
evolution observed with the different successive treatment approaches suggests that if infants do require therapy, the prompt
initiation of a more intensive regimen such as carboplatin–etoposide may be more beneficial.
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Neuroblastoma (NB) is the most common extracranial solid
tumour of childhood. Over one-half of patients present with
metastatic disease at diagnosis. In the case of widespread disease
with bone and bone marrow metastases in children over 1year of
age, a dismal outcome is observed despite intensive multimodal
therapy. Conversely, a small group of patients with disseminated
disease have a good prognosis. This is a salient feature of NB 4s, a
‘special’ stage of disseminated NB first described in 1971 by Evans
et al (1971) as stage IVs and referring to a small primary tumour
with disease dissemination restricted to the liver, skin and/or bone
marrow. Other staging systems have been described in the past for
this disease. However, more recently, in order to create a uniform
classification system, the International Neuroblastoma Staging
System (INSS) has been implemented and is now used universally
(Brodeur et al, 1988, 1993). The INSS criteria for stage 4s NB are
similar to those of the original Evans’ classification, but restrict
this diagnosis to children of less than 1 year at diagnosis and with
less than 10% of bone marrow involvement (Brodeur et al, 1993).
Stage 4s NB represents approximately 7–10% of all NB cases. Its
hallmark is the possibility of spontaneous regression despite a
large tumour burden, and an overall good prognosis (Pritchard
and Hickman, 1994; Matthay 1998; Hero et al, 2000). Indeed, large
retrospective studies have demonstrated disease-free survival rates
of 57–87% (Evans et al, 1980; Mancini et al, 1984; Katzenstein et al,
1998). More recently, a large prospective study has demonstrated a
5-year overall survival (OS) of 92% (Nickerson et al, 2000). Despite
the fact that most infants have a good outcome with little or no
treatment, neonates especially are at risk due to respiratory, renal,
gastrointestinal impairment or coagulation disorders caused by
massive hepatomegaly. Thus, chemotherapy and/or radiation
therapy have been administered to those infants who present with
progressive disease (PD) and life-threatening symptoms. However,
in all cases, the potential benefits of early cytotoxic treatment need
to be weighed against the possible adverse early and late effects of
a medical intervention, and the decision of who, when, how and for
how long to treat remains controversial (Hartwig et al, 1999).
Objective criteria with a scoring scale indicating the degree of
organ compromise have been described as a basis for treatment
decisions (Hsu et al, 1996), but this scoring system is not
universally employed. Furthermore, several well-defined para-
meters have been associated with a poor prognosis in stage 4s NB.
These include age less than 2 months at diagnosis, biological
markers such as elevated serum lactate dehydrogenase (LDH),
ferritin or neuron-specific enolase (NSE) levels, histopathological
as well as genetic markers such as N-myc amplification (NMA) and
tumour diploidy (Seeger et al, 1985; Look et al, 1991; Evans et al,
1996; Katzenstein et al, 1998). Chromosome 1p deletion has also
been suggested to be associated with a poor outcome in NB Received 3 July 2002; revised 30 April 2003; accepted 25 May 2003
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l(Caron, 1995). When indicated, a wide range of different first-line
treatment approaches have been used, ranging from liver radio-
therapy as first-line treatment to more or less intensive
chemotherapy regimens, but the heterogeneity of these approaches
hamper the comparison of treatment results.
We now report on the French Society of Paediatric Oncology’s
experience with stage 4s NB during the last decade. We describe
the clinical evolution of this disease in a series of 94 patients who
were treated according to different successive therapeutic strate-
gies. We furthermore aim to define clinical and biological
prognostic factors in this series of patients.
PATIENTS AND METHODS
Between 1990 and 2000, all infants with NB treated in centres of the
SFOP (French Society of Paediatric Oncology) and aged less than 1
year at diagnosis were registered in the NBL90 study, with data
provided by the treating physician. Stage 4s NB was defined
according to the revised INSS criteria, on the basis of the provided
data, including infants with small primary tumours and metastasis
limited to skin, liver and bone marrow, without bone involvement
(Brodeur et al, 1988; Brodeur et al, 1993). Those patients who did
not undergo surgical evaluation of the primary tumour required by
the INSS criteria were classified according to clinical and
radiological findings. Infants with stage 4s NB were included in
this study if clinical and follow-up data were available for
retrospective data analysis. Patients with liver involvement due
to contiguous tumour spread from a large intra-abdominal
primary were excluded.
The diagnosis of NB was confirmed histologically either by
surgical biopsies or more frequently cytologically by percutaneous
fine-needle aspirates. Staging procedures at diagnosis involved
evaluation of the extent of the primary tumour by ultrasound,
computed tomography or magnetic resonance imaging, and level
of urinary catecholamine metabolites on 24-h urine samples,
standardised on urinary creatinine excretion. In order to evaluate
metastatic spread, appropriate skeletal radiological imaging and
MIBG scanning were performed, as well as bone marrow aspirates
and bone marrow biopsies whenever possible. Local laboratories
determined serum LDH, ferritin and NSE levels at diagnosis. N-
myc copy number was determined in one of three SFOP reference
laboratories by Southern blot analysis, dot blot, or semiquantita-
tive polymerase chain reaction. Chromosome 1p status was
determined by fluorescence in situ hybridisation or by search for
loss-of-heterozygosity (LOH) at polymorphic loci.
Treatment consisted of supportive care for all infants. Life-
threatening symptoms with respiratory or cardiovascular compro-
mise were indications for treatment by either radiation therapy or
chemotherapy. In some instances, very large but stable tumours
were also treated due to threatening decompensation. The decision
regarding which treatment plan to follow was taken by the treating
physician according to the recommendations of the SFOP.
Radiation therapy consisted of hepatic irradiation at a total dose
of 4.5Gy administered in three fractions of 1.5Gy on three
consecutive days. Different chemotherapy regimens were used.
Until 1996, first-line chemotherapy consisted of the CO regimen
(cyclophosphamide, 5mgkg
 1day
 1, days 1–3 and vincristine,
0.05mgkg
 1day
 1, day 1), administered every 2 weeks for a
total of up to nine courses. More intensive chemotherapy was
delivered according to the CE regimen (carboplatin,
6.6mgkg
 1day
 1, days 1–3 and etoposide, 5mgkg
 1day
 1, days
1–3), repeated after 21 days, which was used as a second-
line chemotherapy before and as a first-line chemotherapy regimen
after 1996. Other second-line treatment schedules consisted of the
CADO regimen (cyclophosphamide 10mgkg
 1day
 1, days 1–5,
vincristine 0.05mgkg
 1day
 1, days 1 and 5, and doxorubicin
2mgkg
 1day
 1, day 5) or the etoposide–cisplatin regimen
(etoposide 3.3mgkg
 1day
 1, days 1–5 and cisplatin
1.3mgkg
 1day
 1, days 1–5). For the two latter schedules, doses
were reduced to 2/3 where body weight was less than 10kg. Five
patients received high-dose chemotherapy (Busulphan–melpha-
lan, BCNU-VM26-carboplatin, or carboplatin–melphalan) fol-
lowed by autologous bone marrow or peripheral stem cell
rescue. All chemotherapy courses were only commenced when
the absolute neutrophil count was X0.5 10
6ml
 1.
Complete remission was defined as an absence of clinical or
radiological evidence of disease and normalisation of urinary
catecholamines.
Statistical analysis
OS was calculated from the date of diagnosis. Survival rates were
estimated according to the Kaplan–Meier method, and survival
rates between subgroups of patients were compared using the log-
rank test. Owing to the small number of events in this cohort of
patients, and because all biologic parameters could not be
determined for every patient, only univariate analyses were
performed.
RESULTS
Population
A total of 97 patients were treated for stage 4s NB in centres of the
SFOP between 1990 and 2000. For three patients, insufficient
clinical data were available, and they were excluded from this
study. Thus, 94 infants met the criteria for inclusion in this study,
with a mean follow-up (FU) of 64 months (range 17–133 months).
There were 50 boys and 44 girls, with a mean age at diagnosis of 66
days (range 0–261 days). The localisation of the primary tumour
was most frequently abdominal (82 out of 94, 85%), with 13
patients presenting with bilateral adrenal disease, and two patients
presenting with abdominal dumbbell tumours. Primary cervical
and thoracic tumours were less frequent, and in five cases, the
primary tumour could not be localised (Table 1). Most tumours
showed hepatic dissemination (87 out of 94, 92%), with bone
marrow and skin metastasis occurring much less frequently.
Medical treatment
According to the therapeutic strategy, infants without life-
threatening symptoms were observed clinically and received
supportive treatment only. A total of 37 out of 94 patients (40%)
did not present with life-threatening clinical symptoms initially
and thus did not require medical intervention. However, four of
these patients presented with disease progression later and
received chemotherapy at the time of progression. Two others
experienced disease progression without worsening of clinical
symptoms, and showed subsequent spontaneous regression. All
these patients are alive, 31 are in complete (CR) and six in partial
remission (PR), with a mean FU of 57 months. However, one
patient who did not receive any medical treatment for stage 4s NB
is currently being treated for acute lymphoblastic leukaemia which
was diagnosed 25 months later (Figure 1).
In all, 57 infants (60%) presented with life-threatening
symptoms and required active treatment. Between 1990 and
2000, three different therapeutic strategies were recommended
consecutively as first-line treatment. These consisted of liver
radiotherapy (1990–1993), of the CO regimen (1994–1996), and of
the CE regimen (1997–2000). In some cases, the CO regimen was
also used as first-line treatment before 1993 and after 1997
(Table 2).
The therapeutic strategy recommended between 1990 and 1993
consisted of liver radiotherapy first followed by chemotherapy
should radiotherapy prove to be insufficient. In total, 10 infants
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lwere treated with radiotherapy first. Among them, radiotherapy
was the only treatment for two, one of whom relapsed 8 months
after diagnosis and died. Eight others received chemotherapy in
addition to liver irradiation (CO7second-line chemotherapy), and
one of these patients also received high-dose chemotherapy
followed by autologous stem cell rescue for hepatic and pulmonary
relapse. One of these patients died early of PD, whereas the others
are in CR (six patients (pts) or PR (one pt) with a mean FU of 98
months.
After 1993, a new treatment strategy was adopted which now
consisted of chemotherapy with the CO regimen as first-line
treatment. In total, 41 infants were treated with this schedule over
the whole 10-year period. The mean delay between diagnosis and
the first course of CO was 21 days (range 0–51 days), and a mean
of four courses were administered (range 1–9 courses), either until
tumour regression occurred or until a switch to second-line
treatment. Only 17 of these patients (41%) did not receive second-
line therapy, two of whom died due to disease progression,
whereas 15 are in CR (14pts) or PR (1pt) with a mean FU of 80
months. Seven patients received liver radiotherapy following first-
line treatment with CO. Two of these patients have died of PD,
whereas five are alive in CR (four pts) or PR (one pt), with a mean
FU of 68 months. Finally, following a first-line treatment regimen
by CO 17 patients received second-line chemotherapy, followed by
high-dose chemotherapy with autologous stem cell rescue in four
cases, in one case due to the presence of amplification of the N-
myc oncogene (NMA), and in three cases for progression to stage 4
disease. Seven of these patients have died due to PD (six cases) or
toxicity (one case), whereas 10 are alive in CR (nine pts) or PR
(one pt), with a mean FU of 58 months.
Altogether, first-line treatment including liver irradiation
and/or the CO regimen was effective for only 24 out of 51
infants (45%), whereas second-line chemotherapy was needed in
21 cases.
In most cases, second-line chemotherapy consisted of two
courses of the CE regimen. In all, 19 patients received this regimen
as second-line treatment. The mean delay between diagnosis and
the first CE course was 155 days (range 23–432 days), and the
mean age at the first course of CE was 155 days (range 50–490
days). After two courses of CE, 2 out of 19 patients did not show
any response to this treatment and died, whereas a partial res-
ponse was observed in 17 patients. They either received
two subsequent courses of the same regimen (eight pts) or two
courses of the CADO regimen (nine pts). Seven of these patients
relapsed later, and five of these patients have died (one from
toxicity, four from disease), whereas 12 are alive in PR (two pts) or
CR (10pts).
After 1996, the CE regimen was recommended as first-
line treatment for all infants presenting with life-threatening
symptoms and was given to six patients. The mean delay between
diagnosis and chemotherapy was 15 days (5–65 days). Tumour
response was observed after two courses of CE in all six patients,
and none required any further treatment. All are alive in CR (five
pts) or PR (one pt) with a mean FU of 26 months (range 17–37
months).
The toxicity of the CE regimen was mainly haematological and
always manageable, with a mean delay between the first and
second course of 21 days (16–25 days). Neutropenia was observed
after four courses, and anaemia requiring red cell transfusion after
two courses. Two patients presented with minor infectious
complications. No other complications were observed with this
regimen.
Outcome
The 3-year OS of this population was 88% (77.6%) (Table 3,
Figure 2). No deaths later than 3 years after diagnosis were
observed. The site of the primary tumour was not of prognostic
significance in this population (Table 3), nor the localisation of
metastatic involvement. Although not statistically significant, there
was a tendency for infants younger than 3 months at diagnosis to
fare worse than those older than 3 months (log-rank test, Po0.06).
The strongest indicator of poor prognosis was the necessity of
medical intervention. Indeed, the OS of the 37 infants who received
supportive measures only was 100%, vs 79.8% for those who
Table 1 Localisation of the primary tumour and of metastasis in 94 infants with stage 4s neuroblastoma
Metastasis
Localisation of the primary tumour Liver Bone marrow Lymph nodes Skin Other
Abdominal 67 (37 left, 30 right) 63 19/60 evaluated 6 9 1
Abdominal (bilateral) 13 12 4/12 evaluated 1 3 0
Abdominal (dumbbell) 2 0 1 0 1 0
Thoracic 4 4 2 0 0 0
Cervical 2 2 1 0 1 0
Cervical and thoracic 1 1 0 0 0 0
Unknown 5 5 0 0 2 0
Total 94 87 27/86 evaluated 7 16 1
Table 2 Number of patients treated according to different treatment strategies between 1990 and 2000
First-line treatment
Time period Patients (total) Supportive treatment only Liver radiotherapy CO CE
1990–1993 41 12 10 19 0
1994–1996 30 15 0 15 0
1997–2000 23 10 0 7 6
94 37 10 41 6
CO¼cyclophosphamide–vincristine; CE¼carboplatin–etoposide.
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lrequired medical treatment (log-rank test, P¼0.0049). Thus, those
who did require medical intervention fared significantly worse.
Surgical treatment
Surgical resection of the primary tumour was attempted in the
majority of cases (69 out of 94pts, 73%), with a mean delay of 154
days (range 0–492 days) after diagnosis. Liver metastases were
detected peroperatively in three patients leading to a secondary
diagnosis of stage 4s NB. For 66 other patients, surgical resection
of the primary tumour was performed either after a period of
observation (28 out of 37pts, 75%), or after completing the various
primary treatment schemes (38 out of 57pts, 66%). Parietoplasty
was performed additionally in four cases. For 25 patients (27%)
surgical resection of the primary tumour was not attempted. In five
cases, no primary tumour could be identified. In all, 20 other
patients did not undergo resection, seven of whom had failed to
respond to medical treatment and died. For the 13 others the
decision to refrain from surgery was taken either on account of the
primary tumour’s localisation or in accordance with the more
recent recommendations leaving the decision of surgery to the
treating physician. The OS of patients who did not undergo
resection of the primary tumour was significantly poorer than that
of the patients who were operated (log-rank test, P¼0.0018,
Table 3).
Biochemistry and molecular biology results
Urinary catecholamines (HVA, VMA, dopamine) and serum LDH,
ferritin and NSE levels were determined at diagnosis for 92, 34, 39
and 43 patients, respectively. As shown in Table 3, patients
with elevated urinary dopamine, serum ferritin or NSE levels
had a worse outcome than those with normal levels. N-myc copy
number was evaluated in 63 out of 94 cases (67%), of whom
four had NMA. All patients with NMA have died of disease
(Table 3). Chromosome 1p status was determined in 23 patients,
six of whom had a chromosome 1p deletion, and three of whom
have died, also resulting in a significantly worse survival rate
(Table 3).
DISCUSSION
In this retrospective study, we have analysed the outcome of 94
infants presenting with stage 4s NB in SFOP centres between 1990
and 2000. All were classified according to the INSS criteria
(Brodeur et al, 1993), and bone metastases were excluded in all
cases by skeletal surveys (63 out of 94pts, 67%), MIBG scanning
(84 out of 94 pts, 89%) and/or bone scans (14 out of 94pts, 15%).
Strict INSS staging does not include stage 4s NB infants with
tumoral bone marrow infiltration exceeding 10%, which has been
reported as extremely rare (one patient in 80, Nickerson et al,
2000). In our study, the degree of bone marrow involvement was
not taken into account.
This study confirms that stage 4s NB is associated with
an excellent survival rate. Indeed, the OS is 88% and com-
parable to previous studies (Suarez et al, 1991; De Bernardi
et al, 1992; Strother et al, 1995; Van Noesel et al, 1997; Katzenstein
et al, 1998; Nickerson et al, 2000). We confirm that over one-
third of patients have clinically favourable tumours without
organ dysfunction despite widespread disease, and that for these
patients careful observation is sufficient with a survival rate of
100%.
Two-third of patients required medical intervention. However,
decisions regarding medical treatment were not taken homo-
geneously. First, the attitudes regarding large but stable tumours
without major organ compromise depended on the investigator.
Indeed, in some cases, treatment was initiated for large tumours in
the absence of spontaneous regression because of a threat of
decompensation. Second, for some patients with PD, a decision to
treat was taken after a period of observation, and we have
arbitrarily grouped infants for whom this occurred within 60 days
following diagnosis with those who were symptomatic and
required treatment immediately at diagnosis. This definition may
account for the higher percentage of infants requiring initial
treatment in our study as compared to other published series
(Nickerson et al, 2000). Finally, life-threatening symptoms were
often defined subjectively according to the treating physicians
rather than to objective scoring systems (Hsu et al, 1996). These
observations underline the necessity of objective criteria for
treatment decisions.
Patients with life-threatening symptoms received medical
treatment according to several different treatment strategies over
the past decade. Radiotherapy as first-line treatment proved
unsatisfactory, as it was sufficient treatment in only 20% of
patients. Two different first-line chemotherapy schedules were
First-line
treatment: 
Radiotherapy
n =10
CO
n =4
CO and
second-line chemotherapy
n =4 
No other
treatment
n =2 
Second-line
treatment: 
Outcome:
DOD
n =1
CR/PR
n =3
CR/PR
n =4
DOD
n =1
CR
n =1
Supportive
only
n =37 
No other 
immediate
treatment
n =33
CO
n =1
Second-line
chemotherapy
n =3
CR
n =1
CR/PR
n =3
CR/PR
n =33
First-line
treatment: 
CO
n =41
Second-line chemotherapy
(with or without radiotherapy)
n =17
Radiotherapy
n =7
No other immediate
treatment 
n =17
Second-line
treatment: 
Outcome:
DOD
n =2
CR/PR
n =15
CR/PR
n =5
DOD/DOT
n =7
CR
n =10
CE
n =6
No
other
treatment
n =6 
CR/PR
n =6
DOD
n =2
A
B
C
D
Figure 1 First- and second-line treatment of 94 patients with stage 4s
neuroblastoma, and outcome. CO-cyclophosphamide–vincristine regimen;
CE-carboplatin–etoposide regimen. DOD/DOT-dead of disease/dead of
toxicity. CR/PR-complete/partial remission.
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lproposed consecutively. The first treatment schedule (CO) also
proved to be unsatisfactory as it was sufficient in only 34% of
patients, the others receiving either additional radiotherapy and/or
second-line chemotherapy with the CE regimen. This regimen used
as first-line treatment may be more promising as it was the only
treatment given to the six latest infants resulting in a 100% survival
rate. Altogether, 12 patients died of disease. Nine of these,
including two patients with NMA, presented with relentless disease
progression either during first-line treatment (seven pts), or
following hepatic recurrence (two pts with NMA). Disease
progression was mainly hepatic in eight cases, leading to major
organ failure, or pulmonary and hepatic in one case. Three other
patients, including two patients with NMA, relapsed as aggressive
stage 4 disease. These observations suggest that in patients with
rapidly expanding intra-abdominal disease, earlier and more
intensive treatment may be necessary.
As already reported, very young infants had a worse prognosis
(De Bernardi et al, 1992; Katzenstein et al, 1998; Nickerson et al,
2000). In previous studies, infants less than 2 months at diagnosis
were found to fare worse, although in some other studies the
threshold was 1 or 3 months old. In our study, the age of 3 months
was the most discriminating, and 11 out of 12 patients who died of
disease were younger than 3 months at diagnosis.
Surgical resection of the primary tumour in children with stage
4s NB has been recommended in the past, and has been associated
with a favourable outcome (Martinez et al, 1992). However, such
an intervention may also be fraught with significant side effects in
small infants, and its systematic application is controversial. In our
study, over two-third of all patients underwent surgical resection
of the primary tumour, in most cases after a period of observation
or after completion of primary medical treatment. Interestingly,
those who did not undergo resection of their primary tumour fared
worse than those who were operated. These data must be
interpreted with caution as they may reflect the fact that in many
cases, the absence of surgical resection concerned infants with
disease non responsive to medical treatment. Following more
recent reports suggesting that resection of the primary tumour
does not significantly contribute to outcome, the decision to
perform surgery, although recommended, was left to the individual
physicians (Guglielmi et al, 1996).
Although strict staging according to the INSS criteria does not
take into account bilateral tumours, such patients were included in
our study if all other INSS criteria were fulfilled (Nickerson et al,
2000). Indeed, in 13 of 94 patients (13%) bilateral adrenal disease
was demonstrated by imaging studies showing bilaterally enlarged
adrenal glands. This incidence is slightly higher than that of 6%
reported previously (Nickerson et al, 2000). In total, 10 of these
patients underwent surgery, either as resection of the larger
primary (eight cases), or as complete resection of one and partial
resection of the other primary (two cases). After surgery, no local
recurrence was observed for any of these patients.
Among the biological and genetic factors studied, NMA was the
strongest predictor of a poor outcome. Indeed, all infants who
presented NMA died of PD. NMA is rare in stage 4s NB, occurring
in less than 10%, but has been strongly associated with a poor
outcome in all studies but one (Tonini et al, 1997; Van Noesel et al,
1997; Katzenstein et al, 1998). Our series of patients confirms NMA
as an adverse prognostic factor. Other parameters associated with
Table 3 OS and prognostic factors in 94 infants with stage 4s neuroblastoma
Parameter N 3-year OS (%) (72s.e.) P (log-rank)
Total population 94 88 (77.6)
Age at diagnosis p60 days 51 83 (712.2) 0.18
460 days 43 93 (78)
p90 days 62 82 (711.4)
490 days 32 96 (76) o0.06
p120 days 73 84 (79.8)
4120 days 21 100 0.06
Primary tumour Abdominal 82 89 (77.8)
Extra-abdominal 7 71 (731.2) 0.12
Metastasis No liver metastasis 7 100
Liver metastasis 87 87 (78.2) 0.33
No cutaneous metastasis 78 88 (78.2)
Cutaneous metastasis 16 87 (716.8) 0.87
No bone marrow metastasis 59 86 (710)
Bone marrow metastasis 27 88 (713) 0.75
Medical treatment Supportive 37 100
chemotherapy and/or radiotherapy 57 80 (711.8) 0.0049
Surgery Resection of primary 69 94 (76.6)
No resection of primary 25 71 (718) 0.0018
Urinary dopamine p2500nmolmmol
 1 creatinine 59 93 (77.4)
42500nmolmmol
 1 creatinine 22 78 (718) o0.05
Serum LDH p600IUl
 1 12 100
4600IUl
 1 22 85 (716.4) 0.23
Serum ferritin p280ngml
 1 30 93 (79)
4280ngml
 1 96 6 ( 729) 0.03
Serum NSE p100nmolml
 1 32 100
4100nmolml
 1 11 54 (727.8) o0.0005
N-myc status No NMA 59 93 (76.8)
NMA 4 0 o0.0005
1p status No 1p deletion 17 100
1p deletion 6 44 (738.2) 0.0016
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la poor outcome were elevated urinary dopamine excretion as well
as elevated serum ferritin and NSE levels, in accordance with
previous reports. In our study, chromosome 1p deletion was also
associated with a poor outcome. Interestingly, among the 13
patients who died, all but one had at least one unfavourable
biological or genetic marker, the patient with only favourable
biological and genetic parameters having died of treatment toxicity
rather than disease progression. Other biological and genetic
factors such as low telomerase activity, low expression of nerve
growth factor and its receptor Trk-A, tumour diploidy and gain of
chromosome 17q material have been associated with poor outcome
in NB (Bown et al, 1999). Further studies making use of recent
technological advances such as DNA microarrays may allow the
identification of factors associated with tumour regression and
thus facilitate treatment decisions.
In conclusion, the outcome observed with the different
successive treatment approaches suggests that if infants with stage
4s NB do require therapy, a more intensive chemotherapy may be
more beneficial. Indeed, in all six patients who received a more
intensive treatment by the CE regimen, only two chemotherapy
courses were required. Although no randomised trial was
performed and although patient numbers are low and follow-up
short, the results suggest that a prompt initiation of a more
intensive treatment may be necessary in order to push the NB cells
towards the regression pathway. If this is achieved early, further
intensive treatment may possibly be avoided. In this report, the CE
regimen proved to be associated with a high response rate and
good clinical tolerance when used as second-line or as first-line
therapy, a schedule which has also shown good response rates and
clinical tolerance in infants with localised, unresectable NB (Rubie
et al, 2001). The CE regimen is now being proposed as first-line
therapy in the NB99 Infant SIOP study for patients with stage 4s
NB who do require medical intervention.
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Figure 2 (A) Overall survival (OS) of 94 children with stage 4s
neuroblastoma. At 3-year OS (72SE) was 88% (77.6). (B)O So f6 2
infants younger than 3 months at diagnosis, vs 32 infants older than 3
months at diagnosis. At 3-year OS (72s.e.) was 83% (712.2) and 93%
(78) in children younger and older than 3 months, respectively (Po0.06,
log-rank test). (C) OS of 37 asymptomatic infants at diagnosis, vs 57 infants
who required treatment. At 3-year OS (72s.e.) was 100 and 80%
(711.8) for those who did not and those who did require treatment,
respectively (Po0.005, log-rank test).
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